Document:

Exhibit 10.11

 

THIRD AMENDMENT TO LICENSE AGREEMENT FOR ANTI-HER2 ANTIBODIES

 

This Third Amendment to License Agreement for Anti-HER2 Antibodies (the “3rd Amendment”) is made effective as of the date of the last signature below (the “3rd Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), having its principal business office at 830 Winter Street, Waltham, Massachusetts 02451, and Genentech, Inc., a Delaware corporation (“Genentech”), having its principal business office at 1 DNA Way, South San Francisco, California 94080.  ImmunoGen and Genentech are herein sometimes referred to as a “Party” and collectively as the “Parties.”

 

WHEREAS, ImmunoGen and Genentech are parties to that certain License Agreement dated as of May 2, 2000, as amended May 3, 2006 and March 11, 2009 (the “License Agreement”); and

 

WHEREAS, the Parties have agreed to modify the terms of the License Agreement, specifically by revising the formula for computing “Foreign Currency Exchange;”

 

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Parties agree and covenant as follows.

 

1.                                      Foreign Currency Exchange.  Section 4.5(b) of the License Agreement is deleted in their entirety and replaced with the following:

 

Foreign Currency Exchange. All amounts payable and calculations made hereunder shall be in United States dollars. Net Sales and any other amounts related to the calculation of any royalty payable hereunder which are not recorded in United States dollars shall first be converted into Swiss Francs and then into United States dollars using Roche’s then current standard foreign currency translation practices actually used on a consistent basis in preparing its audited financial statements (currently YTD average rate as reported by Reuters).

 

2.                                      Miscellaneous.  Capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the License Agreement.  The License Agreement remains in full force and effect, as amended by this 3rd Amendment.  References in the License Agreement to “Agreement” mean the License Agreement as amended by this 3rd Amendment.

 

[Signature Page Follows]

 

 

IN WITNESS WHEREOF, the Parties have caused this THIRD AMENDMENT TO LICENSE AGREEMENT FOR ANTI-HER2 ANTIBODIES to be duly executed, effective as of the 3rd Amendment Effective Date, by their duly authorized officers.

 

	
IMMUNOGEN, INC.
    	
 
    	
GENENTECH,   INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/   Gregory D. Perry
    	
 
    	
By:
    	
/s/   Steve Krognes
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Gregory   D. Perry
    	
 
    	
Name:
    	
Steve   Krognes
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
EVP   & CFO
    	
 
    	
Title:
    	
CFO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
18   Dec 2012
    	
 
    	
Date:
    	
13   Dec 2012
    

 

2Exhibit 10.1

 

FOURTH AMENDMENT TO THE VIVUS, INC.

 

LELAND F. WILSON EMPLOYMENT AGREEMENT

 

DATED DECEMBER 20, 2007

 

This Fourth Amendment to the VIVUS, Inc. Leland F. Wilson Employment Agreement by and between VIVUS, Inc., a Delaware corporation (the “Company”), and Leland F. Wilson (“Executive”) dated December 20, 2007, with an effective date of June 1, 2007 (the “Effective Date”) is made as of January 25, 2013.

 

WHEREAS, the parties entered into the VIVUS, Inc. Leland F. Wilson Employment Agreement dated December 20, 2007, as amended by the first, second and third amendments thereto (the “Original Agreement”), and the Original Agreement had an initial term of five (5)  years commencing upon the Effective Date (the “Initial Term”).

 

WHEREAS, the parties wish to amend the Original Agreement to extend the Initial Term up to and including June 1, 2014.

 

WHEREAS, the Original Agreement, as set forth in Section 20, provides that any amendments to the Original Agreement must be in a writing executed by the parties.

 

WHEREAS, the parties enter into this Fourth Amendment to amend the Original Agreement as set forth below to allow for an Initial Term commencing on the Effective Date and ending on June 1, 2014.

 

NOW THEREFORE, the parties agree as follows:

 

1.                                      Section 3 of the Original Agreement shall be amended and restated in its entirety to read as follows:

 

3.                                      Term of Agreement.  This Agreement will have an initial term commencing on the Effective Date and ending on June 1, 2014.  On the seventh anniversary of the Effective Date, this Agreement will renew for an additional one (1) year term (the “Additional Term”) unless either party provides the other party with written notice of non-renewal at least ninety (90) days prior to the date of automatic renewal.  If the Company provides Executive with a notice of non-renewal, and such non-renewal is for reasons other than Cause, Executive will be entitled to the amounts and benefits specified in Section 8 of this Agreement.

 

2.                                      This Fourth Amendment may be executed in one (1) or more counterparts, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument.  This Fourth Amendment may be executed by facsimile signature, which shall be deemed to be effective.

 

3.                                      Upon the execution of this Fourth Amendment by the Company and Executive, this Fourth Amendment shall be binding upon the parties to the Original Agreement.

 

1

 

4.                                      Except as set forth above, the remainder of the Original Agreement shall remain in full force and effect and shall be binding on all parties thereto.  All terms not otherwise defined in this Fourth Amendment shall have the meanings prescribed to them in the Original Agreement.

 

IN WITNESS WHEREOF, the parties have duly executed this Fourth Amendment to the VIVUS, Inc. Leland F. Wilson Employment Agreement dated December 20, 2007, as amended to date, as of the date set forth below.

 

	
COMPANY
    	
 
    	
EXECUTIVE
    
	
 
    	
 
    	
 
    
	
VIVUS, Inc.
    	
 
    	
 
    
	
a   Delaware corporation
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   Mark B. Logan
    	
 
    	
/s/   Leland F. Wilson
    
	
(Signature)
    	
 
    	
(Signature)
    
	
 
    	
 
    	
 
    
	
Mark   B. Logan
    	
 
    	
Leland   F. Wilson
    
	
(Print   Name)
    	
 
    	
(Print   Name)
    
	
 
    	
 
    	
 
    
	
Chairman   of the Board
    	
 
    	
N/A
    
	
(Print   Title if signing on behalf of an entity)
    	
 
    	
(Print   Title if signing on behalf of an entity)
    
	
 
    	
 
    	
 
    
	
Dated:   January 25, 2013
    	
 
    	
Dated:   January 25, 2013
    

 

2ex10_143.htm

Exhibit 10.143

 

COMPUWARE CORPORATION

AMENDED AND RESTATED 2007 LONG TERM INCENTIVE PLAN

AMENDMENT NO. 2

 

WHEREAS, Compuware Corporation (the "Corporation") has established the Compuware Corporation Amended and Restated 2007 Long Term Incentive Plan, as amended from time to time (the "Plan"); and

WHEREAS, the Corporation desires to amend the Plan; and

WHEREAS, the Corporation’s board of directors is authorized to amend the Plan pursuant to Section 10.6 of the Plan.

NOW THEREFORE, the Plan is hereby amended, effective January 24, 2013 (including with respect to Awards outstanding on such date), as follows:

1.            Section 1.4(d) of the Plan shall be replaced in its entirety with the following:

(d)           A "Change in Control" shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred:

(i)           any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Corporation (not including in the securities beneficially owned by such Person any securities acquired directly from the Corporation or its Affiliates) representing 35% or more of the combined voting power of the Corporation's then outstanding securities, excluding any Person who becomes such a Beneficial Owner in connection with a transaction described in clause (i) of paragraph (III) below; or

(ii)           the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Corporation) whose appointment or election by the Board or nomination for election by the Corporation's stockholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or nomination for election was previously so approved or recommended; or

(iii)           there is consummated a merger or consolidation of the Corporation or any direct or indirect subsidiary of the Corporation with any other corporation, other than (i) a merger or consolidation immediately following which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of the Corporation, the entity surviving such merger or consolidation or, if the Corporation or the entity surviving such merger is then a subsidiary, the ultimate parent thereof, or (ii) a merger or consolidation effected to implement a recapitalization of the Corporation (or similar transaction) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Corporation (not including in the securities Beneficially Owned by such Person any securities acquired directly from the Corporation or its Affiliates) representing 35% or more of the combined voting power of the Corporation's then outstanding securities; or

  

  

  

 

(iv)           the stockholders of the Corporation approve a plan of complete liquidation or dissolution of the Corporation or there is consummated an agreement for the sale or disposition by the Corporation of all or substantially all of the Corporation's assets, other than a sale or disposition by the Corporation of all or substantially all of the Corporation's assets immediately following which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the board of directors of the entity to which such assets are sold or disposed or any parent thereof.

Notwithstanding the foregoing, a "Change in Control" shall not be deemed to have occurred by virtue of the consummation of any transaction or series of integrated transactions immediately following which the record holders of the common stock of the Corporation immediately prior to such transaction or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially all of the assets of the Corporation immediately following such transaction or series of transactions.

Notwithstanding any other Plan provision, to the extent that any payment subject to Code Section 409A is payable on a Change in Control, an event shall not be considered a Change in Control under the Plan with respect to such payment unless the event is also a “change in ownership,” a “change in effective control” or a “change in the ownership of a substantial portion of the assets” of the Corporation within the meaning of Code Section 409A and regulations thereunder.

"Beneficial Owner" shall have the meaning set forth in Rule 13d-3 under the Exchange Act.

"Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Corporation or any of its subsidiaries, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the Corporation or any of its Affiliates, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities, or (iv) a corporation owned, directly or indirectly, by the stockholders of the Corporation in substantially the same proportions as their ownership of stock of the Corporation.

2.            Except as expressly modified by this Amendment No. 2, the Plan shall remain in full force and effect.

 

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00212-of-00352.parquet"}]]